Immunochemistry services director joins PharmaNet

Will expand large molecule services at US firm

Chris Beaver has joined PharmaNet Development Group, a US provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, as director of immunochemistry services.

Beaver will lead the immunochemistry team within the firm’s bioanalytical laboratories and expand its large molecule services, including assay development and sample analysis for biomarker, ELISA, radioimmunoassays, immunogenicity and cell-based assays.

PharmaNet has two GLP-compliant bioanalytical laboratories located in Princeton, New Jersey and Quebec City, Canada.

You may also like

Manufacturing

Lonza opens capsule drug development-focused site at its Colmar facility

The new addition to the French site will allow customers access to experts and technologies ideal for capsule formulation and development
Research & Development

Adenosine A2a receptor: novel biophysical fragment screening using polymer-encapsulated nanodiscs

Fragment screening is a useful method for hit identification as it offers an efficient and flexible way to identify novel therapeutic starting points that other techniques may have missed because of the small molecular size of the fragments
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Research & Development

RSSL opens 3D imaging and metrology laboratory for end-to-end research and analysis

The laboratory will offer, micro-CT, microscopy and spectroscopy services for its pharmaceutical and medical device partners
Manufacturing

Ensuring cGMP compliance in cell and gene therapy manufacturing

3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
Manufacturing

Quotient Sciences and Vasa Therapeutics announce dosing of first subjects in VS-041 novel heart failure trial

The trial is designed to evaluate the safety, tolerability, and pharmacokinetics of VS-041 in healthy volunteers
Regulatory

Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer

The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
Subscribe now